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Abstract: This study investigated whether vascular endothelial growth factor (VEGF), soluble 
intercellular adhesion molecule-1 (sICAM-1), and pigment epithelium-derived factor (PEDF) 
influence the visual prognosis of patients with macular edema and branch retinal vein occlusion 
(BRVO). In 47 consecutive patients (47 eyes) undergoing vitrectomy, retinal thickness was 
examined by optical coherence tomography. Best-corrected visual acuity and the vitreous fluid 
levels of VEGF, sICAM-1, and PEDF were also determined. Patients were followed for at least 
6 months after surgery. Vitreous fluid levels of VEGF and sICAM-1 were significantly lower 
in the patients with more marked improvement of visual acuity after vitrectomy, while PEDF 
was significantly higher. VEGF and sICAM-1 levels were significantly higher in patients with 
greater postoperative improvement of macular edema, while PEDF was significantly lower. In 
BRVO patients, vitreous fluid levels of VEGF, sICAM-1, and PEDF may influence both the 
response of macular edema to vitrectomy and the visual prognosis.
Keywords: branch retinal vein occlusion, macular edema, vitrectomy, vascular endothelial 
growth factor, soluble intercellular adhesion molecule-1, pigment epithelium-derived factor
Introduction
Branch retinal vein occlusion (BRVO) is a common retinal vascular disease that 
often leads to macular edema, which is the commonest reason for visual impair-
ment in this disease.1,2 We recently reported that the ocular fluid levels of several 
  molecules, including vascular endothelial growth factor (VEGF), soluble intercellular 
  adhesion molecule-1 (sICAM-1), and pigment epithelium-derived factor (PEDF), 
had an independent influence on retinal vascular permeability in BRVO patients 
with macular edema.3,4 Therefore, changes in the vitreous levels of these molecules 
may influence the development of macular edema associated with BRVO and may 
also be related to improvement of macular edema in BRVO patients after pars plana 
vitrectomy (PPV).
We recently reported that a decrease of VEGF in the vitreous fluid was   associated 
with improvement of visual acuity and macular edema after PPV in patients with 
BRVO. 5 However, little is known about the relationship between occurrence of 
macular edema secondary to BRVO and the vitreous levels of sICAM-1 and PEDF. 
Therefore, we evaluated the outcome of PPV for the treatment of macular edema 
in patients with BRVO, measured the vitreous fluid levels of sICAM-1, PEDF, and 
VEGF, and   examined the relationship between these molecules, improvement of 
the final   best-corrected visual acuity (BCVA), and improvement of macular edema 
after PPV .Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Materials and methods
Patients
This study was performed in accordance with the Helsinki 
Declaration of 1975 (1983 revision), and the institutional 
review boards of Tokyo Women’s Medical University and 
Eguchi Eye Hospital both approved the protocol for   collection 
and testing of vitreous fluid. Written informed consent was 
obtained from each subject following an explanation of 
the purpose and potential adverse effects of the procedure. 
The patients all underwent PPV at Tokyo Women’s Medical 
University Hospital or Eguchi Eye   Hospital, and undiluted 
vitreous fluid samples were harvested at the start of surgery. 
Consecutive patients presenting with BRVO between 
  December 2006 and November 2009 were screened according 
to the criteria listed below and 48 patients were enrolled. 
Complete data were available for 47 of the 48 patients enrolled, 
while one patient was lost to follow-up because of referral to 
another hospital. The indications for PPV were 1) clinically 
detectable diffuse macular edema or cystoid macular edema 
persisting for more than 3 months, 2) a   best-corrected visual 
acuity worse than 20/40, and 3) persistent macular edema 
despite retinal photocoagulation.
The Branch Vein Occlusion Study demonstrated the 
effectiveness of argon laser photocoagulation for BRVO, but 
it was recommended that this should not be performed within 
3 months of occlusion because spontaneous improvement 
may occur during that period.6 Accordingly, all 11 patients 
(11 eyes) who underwent focal laser photocoagulation for 
macular edema (mean: 242 shots; range: 120–374 shots) 
were treated for more than 3 months after the occurrence 
of BRVO. Absence of posterior vitreous detachment can 
  contribute to persistent macular edema in patients with retinal 
vascular occlusion,7 and Saika et al reported the   effectiveness 
of vitrectomy combined with surgical posterior vitreous 
detachment for macular edema in BRVO patients.8 Therefore, 
we performed vitrectomy for more than 3 months after the 
occurrence of BRVO in patients with clinically detectable 
diffuse macular edema, cystoid macular edema, or persistent 
macular edema despite photocoagulation.
All of the patients had significant macular edema, which 
was defined as retinal thickening of at least one optic disk 
area in size that involved the fovea.9 Exclusion criteria were 
1) ocular surgery within the previous 6 months, 2) diabetic 
retinopathy, 3) intravitreous injection of anti-VEGF agents or 
triamcinolone acetonide, and 4) a history of ocular inflamma-
tion or vitreoretinal disease. A total of 25 of the 47 patients 
underwent PPV combined with cataract surgery. During the 
6-month follow-up period after surgery, cataract extraction 
was not performed in the other 22 patients without baseline 
cataracts, and additional scatter laser photocoagulation was 
not done in any of the patients.
Fundus findings
Careful biomicroscopic examination was performed with 
a fundus contact lens. Fundus findings were confirmed 
preoperatively by standardized fundus color photography 
and fluorescein angiography, which was performed with a 
Topcon TRC-50EX fundus camera, an image-net system 
(Tokyo Optical Co Ltd, Tokyo, Japan), and a preset lens with 
a slit-lamp. BCVA was measured before and after PPV in 
decimal units, and the data were converted to the logarithm 
of the minimum angle of resolution (logMAR) scale.
Both preoperative and operative fundus findings were 
recorded for each subject. A masked grader independently 
assessed ischemic retinal vascular occlusion on fluorescein 
angiograms. The ischemic region of the retina was   measured 
with the public domain Scion Image program (Scion 
Corporation, Frederick, MD), as reported previously.10–12 
In brief, the disk area was outlined on a digital fluorescein 
photograph using a cursor and then was measured, as was 
the nonperfused area. Sites of retinal photocoagulation were 
excluded when calculating the nonperfused area, which was 
divided by the disk area as an index of retinal ischemia.
In each subject, optical coherence tomography (OCT) 
was performed with a unit from Zeiss-Humphrey Ophthalmic 
Systems (Dublin, CA) within 1 week before PPV . The fundi 
were scanned with the measuring beam focused on horizontal 
and vertical planes crossing the central fovea, the location 
of which was determined from the fundus photograph and 
by the patient’s fixation. (All 47 subjects were able to fix on 
the central landmark during OCT.) Cross-sectional images 
were collected by a single, experienced examiner, who con-
tinued each OCT study until highly reproducible scans were 
obtained. The thickness of the central fovea was defined as 
the distance between the inner limiting membrane and the 
retinal pigment epithelium (including any serous retinal 
detachment). The thickness of the neurosensory retina was 
defined as the distance between the inner and outer neurosen-
sory retinal surfaces,7 and the severity of macular edema was 
graded from the measured foveal thickness. Measurements 
were automatically performed by computer analysis.
Serous retinal detachment was defined as typical subretinal 
fluid accumulation on OCT that resulted in neurosensory retinal 
detachment with low or absent reflectivity anterior to a clearly Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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distinguishable outer band irrespective of the   coexistence of 
cystoid macular edema.13 The 47 BRVO patients included 
20 patients who had serous retinal   detachment (mean age: 
64.9 ± 11.0 years; 12 women and 8 men) and 27 patients without 
it (mean age: 66.7 ± 8.9 years; 14 women and 13 men).
surgical technique
Under local anesthesia, all patients underwent standard 
three-port PPV . All epiretinal materials, the residual cortex, 
and the posterior hyaloid were removed from the retinal 
surface around the macula as completely as possible with the 
assistance of triamcinolone acetonide. The minimum volume 
necessary was injected into the eyeball and then was removed 
as thoroughly as possible at the end of surgery. Intraoperative 
scatter laser photocoagulation was not done for the ischemic 
region of the retina. Peeling of the internal limiting membrane 
was also not done either. All patients were followed up for 
at least 6 months postoperatively.
Measurement of VegF, siCAM-1,  
and PeDF
Samples of undiluted vitreous fluid (300–500 µL) 
were collected into sterile tubes at the time of surgery 
and were rapidly frozen at −80°C. Then sICAM-1 and VEGF 
were measured in vitreous fluid samples as well as in plasma 
by using enzyme-linked immunosorbent assay (ELISA) 
kits for human VEGF (R&D Systems, Minneapolis, MN) 
and sICAM-1 (Bender Med Systems, Burlingame, CA).4 
PEDF was measured in vitreous and plasma samples with a 
human PEDF Sandwich ELISA kit (Chemicon   International, 
  Temecula, CA).3 The VEGF kit detected two of the four 
  isoforms of VEGF, which were VEGF121 and VEGF165. 
Levels of sICAM-1, PEDF, and VEGF in the vitreous fluid 
were within the detection ranges of the assays, with the 
  minimum detectable concentration being 15.6 pg/mL for 
VEGF (intra-assay coefficient of variation (CV): 5.5%; 
interassay CV: 6.9%), 3.3 ng/mL for sICAM-1 (intra-assay 
CV: 5.4%; interassay CV: 7.6%), and 1.95 ng/mL for PEDF 
(intra-assay CV: 5.4%; interassay CV: 7.7%).
statistical analysis
All analyses were performed with SAS software (v. 9.1; SAS 
Institute Inc, Cary, NC). Data are presented as frequencies or 
as the mean ± SD. The paired t test was used to compare the 
retinal thickness and the improvement of BCVA from before 
surgery until 6 months after surgery. The mean improvement 
of visual acuity and percent change of macular edema were 
compared between patients with and without focal laser 
coagulation by Student’s t-test. To investigate the relation 
between each of the factors that we assessed and the percent 
change of macular edema, Spearman’s rank-order correlation 
coefficients were calculated. A two-tailed P value of ,0.05 
was taken to indicate statistical significance.
Results
Patient profile
Among the 47 patients, 26 were women and 21 were men. 
Their mean age was 65.9 ± 9.8 years (range: 43–87 years), 
and the mean duration of BRVO before surgery was 
4.4 ± 1.9 months (range: 3–10 months). A diagnosis of hyper-
tension was based on information from the medical records 
and was defined as current treatment with antihypertensive 
drugs or a blood pressure . 140/90 mm Hg.14 A total of 30 of 
the 47 BRVO patients (63.8%) had hypertension (Table 1).
Changes of visual acuity and foveal 
thickness after PPV
At the initial examination, mean BCVA was logMAR 
0.81 ± 0.42, and it improved significantly to logMAR 
0.52 ± 0.41 by 6 months after PPV (P , 0.001) (Table 2). 
Three patients (6%) showed deterioration of visual acuity, 
including two with prolonged macular edema after surgery 
and one with macular atrophy. The initial mean foveal thick-
ness was 587 ± 165 µm, and it decreased significantly to 
278 ± 114 µm by 6 months after PPV (P , 0.001) (Table 2). 
During surgery, iatrogenic peripheral retinal tears occurred 
in two eyes, but these were successfully treated by endolaser 
photocoagulation and sulfur hexafluoride gas tamponade. 
Postoperatively, neovascular glaucoma did not develop in 
any of the patients after follow-up for 6 months.
BCVA and vitreous factors
When the improvement of BCVA was calculated by sub-
tracting the postoperative BCVA from the preoperative 
Table 1 Baseline clinical features of the BrVO
Findings BRVO (N = 47)
Age (years) 65.9 ± 9.8a
gender (female/male) 26/21
hypertension 30 (63.8%)
Duration of BrVO (months) 4.4 ± 1.9a
Focal retinal photocoagulation 11 (23.4%)
Nonperfused area (disk areas) 30.9 ± 34.8a
Note: aMean ± standard deviation (sD).
Abbreviation: BrVO, branch retinal vein occlusion.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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value, there was a significant negative correlation between 
the   vitreous level of VEGF or sICAM-1 and improvement 
of BCVA. Accordingly, VEGF and sICAM-1 levels were 
significantly lower in patients who showed more marked 
improvement of BCVA after vitrectomy (r = −0.38, P = 0.007 
and r = −0.36, P = 0.010, respectively) (Figure 1A, B). In 
contrast, there was a significant positive correlation between 
the vitreous level of PEDF and improvement of BCVA, so 
the PEDF level was significantly higher in patients with more 
marked improvement of BCVA after vitrectomy (r = 0.32, 
P = 0.028) (Figure 1C). In addition, there was no significant 
difference in the improvement of BCVA between the patients 
with or without focal laser coagulation (P = 0.877).
Foveal thickness and vitreous factors
Improvement of macular edema was evaluated by calculating 
the percent change of macular edema (%∆ME) as follows:
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where MEpr and MEpo correspond to the foveal   thickness 
before vitrectomy and 6 months after surgery, respectively. 
As a result, a significant positive correlation was found 
between the vitreous level of VEGF or sICAM-1 and the 
percent change of macular edema, so VEGF and sICAM-1 
levels were significantly higher in patients with more 
marked improvement of macular edema after PPV 
(r = 0.41, P = 0.004 and r = 0.29, P = 0.046, respectively) 
(Figure 2A, B). In contrast, there was a significant negative 
correlation between the vitreous level of PEDF and the 
percent change of macular edema, meaning that the PEDF 
level was significantly lower in patients who showed more 
marked improvement of macular edema (r = −0.35, P = 0.016) 
(Figure 2C). In addition, there was no significant difference 
in the percent change of macular edema between the patients 
with or   without focal laser coagulation (P = 0.289).
relation between improvement  
of BCVA and clinical factors
Multiple regression analysis was performed to investigate 
the influence of the following factors on BCVA: gender, 
hypertension (present/absent), duration of BRVO (months), 
nonperfused retinal area (disk areas), cataract surgery (yes/no), 
retinal photocoagulation (yes/no), serous retinal detachment 
(present/absent), the vitreous VEGF level, the vitreous 
sICAM-1 level, and the vitreous PEDF level. It was found 
that the vitreous fluid levels of sICAM-1 and PEDF were 
significant independent determinants of the improvement of 
BCVA (P = 0.045 and P = 0.038, respectively) (Table 3).
Discussion
The present study showed that the vitreous fluid levels of 
VEGF and sICAM-1 were significantly higher in BRVO 
Table 2 Clinical outcome of the patients with BrVO
Variable Preoperative 6 months P value
Visual acuity (logMAr) 0.81 ± 0.42a 0.52 ± 0.41a ,0.001
Central macular thickness (µm)   587 ± 165a   278 ± 114a ,0.001
Note: aMean ± standard deviation (sD).
Abbreviations: BrVO, branch retinal vein occlusion; logMAr, logarithm of the 
minimum angle of resolution.
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Figure 1 Correlations between vitreous fluid levels of VEGF, sICAM-1, or PEDF and improvement of BCVA. A) Significant negative correlation between the vitreous level 
of VegF and the improvement of BCVA (r = −0.38, P = 0.007). B) Significant negative correlation between the vitreous level of sICAM-1 and the improvement of BCVA 
(r = −0.36, P = 0.010). C) Significant positive correlation between the vitreous level of PEDF and the improvement of BCVA (r = 0.32, P = 0.028).
Abbreviations: VegF, vascular endothelial growth factor; siCAM-1, soluble intercellular adhesion molecule-1; PeDF, pigment epithelium-derived factor; BCVA, best-corrected   
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Dovepress 
Dovepress
227
Visual prognosis and vitreous molecules after vitrectomy
patients with less marked improvement of BCVA after 
PPV, while the PEDF level was significantly lower in such 
patients. In addition, vitreous fluid levels of sICAM-1 and 
PEDF had a significant influence on the visual outcome 
according to multivariate analysis, although the vitreous 
VEGF level did not. This may have been because the effect 
of VEGF was counteracted by that of sICAM-1due to the 
strong positive correlation between sICAM-1 and VEGF 
levels in the vitreous fluid (data not shown). These findings 
suggest that measurement of these molecules (sICAM-1 and 
PEDF) in the vitreous fluid may be useful for predicting the 
visual prognosis after PPV. The macula is a vital part of the 
retina for detailed vision, especially the fovea that consists 
entirely of cones.15 Histopathologic studies have shown that 
macular edema is associated with swelling of the Müller 
cells, especially in the outer plexiform layer of the neurosen-
sory retina.16–18 VEGF increases vascular permeability,19 and 
VEGF production is upregulated when retinal glial cells are 
exposed to hypoxia.20 VEGF has also been reported to alter 
the conformation of tight junctions between retinal vascular 
endothelial cells.21,22   Furthermore, VEGF increases ICAM-1 
production by capillary endothelial cells in a dose- and time-
dependent manner, while intravitreal injection of VEGF 
at pathophysiologically relevant concentrations increases 
ICAM-1 protein and mRNA levels in retinal vessel walls.23 
It has been suggested that VEGF-induced breakdown of the 
blood–retinal barrier (BRB) partly depends on an interac-
tion with leukocytes, because inhibition of ICAM-1 expres-
sion prevents the breakdown of this barrier when VEGF 
is injected into the eyes of rats,24 while blocking ICAM-1 
activity with a neutral izing antibody suppresses both retinal 
leukostasis and BRB breakdown.24 Thus, VEGF increases 
ICAM-1 expression by capillary endothelial cells and by 
cells of the retinal vessels, suggesting that increased VEGF 
production may lead to upregulation of ICAM-1 expression 
that promotes adhesion of leukocytes to the retinal vessels 
in BRVO patients. On the other hand, injection of PEDF 
into the mice eyes has been shown to prevent an increase of 
vascular permeability,25 and PEDF has also been reported to 
inhibit leukostasis related to diabetes or advanced   glycation 
end products by suppressing ICAM-1 production.26 Because 
VEGF-induced breakdown of the BRB seems to be partly 
dependent on leukocyte stasis,24 as mentioned above, 
the present findings suggest that PEDF may ameliorate 
BRB breakdown and thus prevent an increase of vascular 
  permeability in patients with BRVO. This conclusion is 
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Figure 2 Correlations between vitreous fluid levels of VEGF, sICAM-1, or PEDF and the percent change of macular edema. A) Significant positive correlation between the 
vitreous level of VegF and the percent change of macular edema (r = 0.41, P = 0.004). B) Significant positive correlation between the vitreous level of sICAM-1 and the percent change 
of macular edema (r = 0.29, P = 0.046). C) Significant negative correlation between the vitreous level of PEDF and the percent change of macular edema (r = −0.35, P = 0.016).
Abbreviations: VegF, vascular endothelial growth factor; siCAM-1, soluble intercellular adhesion molecule-1; PeDF, pigment epithelium-derived factor.
Table 3 Results of multivariate analysis of factors influencing the 
improvement of BCVA
Variable Improvement of BCVA (logMAR)
Standard partial  
regression coefficient
P value
gender −0.15 0.354
hypertension 0.19 0.240
Duration of BrVO (months) 0.21 0.176
Nonperfused retinal area  
(disk areas)
0.02 0.936
Cataract surgery 0.13 0.398
retinal photocoagulation −0.09 0.549
serous retinal detachment 0.31 0.088
Vitreous VegF level (pg/mL) −0.14 0.628
Vitreous siCAM-1 level (ng/mL) −0.37 0.045
Vitreous PeDF level (ng/mL) 0.39 0.038
Abbreviations:  BCVA,  best-corrected  visual  acuity;  logMAr,  logarithm  of  the 
minimum angle of resolution; BrVO, branch retinal vein occlusion; VegF, vascular 
endothelial  growth  factor;  siCAM-1,  soluble  intercellular  adhesion  molecule-1; 
PeDF, pigment epithelium-derived factor.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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supported by reports that   intravitreal injection of PEDF 
significantly reduces VEGF-induced   vascular endothelial 
hyperpermeability and BRB breakdown in models of 
  diabetic retinopathy.27,28 Thus, an increase of both VEGF 
and sICAM-1 along with a decrease of PEDF may promote 
the development of macular edema in patients with BRVO, 
after which macular edema causes deterioration of retinal 
function and leads to visual impairment.
In the present study, we found that higher VEGF and 
sICAM-1 levels in the vitreous fluid at the time of PPV were 
significantly associated with more marked postoperative 
improvement of macular edema, as was a lower PEDF level. 
Intravitreal injection of VEGF has been reported to provoke 
retinal edema, dilated and tortuous retinal vessels, and capil-
lary closure in adult primates,29 while treatment with bevaci-
zumab (a monoclonal anti-VEGF antibody) or ranibizumab 
(an Fab fragment that binds and neutralizes all isoforms of 
VEGF-A) improves macular edema in BRVO patients.30–32 
In addition, an anti-ICAM-1 neutralizing antibody has been 
reported to suppress both retinal leukostasis and BRB break-
down.24 Therefore, reduction of the vitreous levels of VEGF 
and sICAM-1 may be one of the mechanisms by which PPV 
improves macular edema in BRVO patients. In agreement 
with this hypothesis, we previously found that the vitreous 
level of VEGF was lower at the time of repeat vitrectomy 
than at the initial operation in patients with macular edema 
due to retinal vein occlusion,33 and it was also reported that 
PPV prevents retinal hypoxia in patients with BRVO.34 We 
recently demonstrated that the vitreous fluid level of PEDF 
has a significant negative correlation with the nonperfused 
area of the retina.3 Accordingly, expression of PEDF may 
be upregulated to prevent retinal hypoxia after PPV , and this 
may be another mechanism by which PPV improves macular 
edema in BRVO patients.
In agreement with our previous findings,5 improvement 
of BCVA and improvement of macular edema did not 
occur in parallel in the present study, although the retinal 
thickness at the central fovea is known to influence visual 
acuity.35,36 In other words, BCVA showed little improve-
ment in some patients even if macular edema was resolved. 
This discrepancy may have arisen because improvement of 
BCVA requires longer than the 6-month follow-up period 
of our study. Alternatively, improvement of BCVA may not 
occur in some patients after macular edema resolves because 
of permanent photoreceptor cell damage due to macular 
ischemia (probably patients who have high levels of VEGF 
and sICAM-1 and a low PEDF level). It is also possible 
that diffuse disorganization of the outer photoreceptor layer 
beneath the fovea or foveal bleeding could impair visual 
  acuity. However, a larger, prospective, randomized study will 
be required to clarify the relationship among these vitreous 
factors and improvement of BCVA or macular edema in 
patients with BRVO.
In conclusion, the vitreous fluid levels of VEGF and 
sICAM-1 were significantly lower in BRVO patients 
who showed more marked improvement of BCVA after 
vitrectomy, while the PEDF level was significantly higher. 
Conversely, VEGF and sICAM-1 levels were significantly 
higher in patients who showed more marked improvement 
of macular edema after PPV, while the PEDF level was 
significantly lower. These results suggest that vitreous fluid 
levels of VEGF, sICAM-1, and PEDF influence the visual 
prognosis and the response of macular edema to vitrectomy 
in BRVO patients.
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